Stories that define us

Building a culture of wellness

At SingHealth, our people are at the heart of all we do. We recognise that a thriving workforce is key to delivering exceptional care, and this begins with prioritising the health and wellbeing of each member in the SingHealth family.

With this commitment in mind, the SingHealth Staff Wellness Office ensures that every staff member feels supported physically, mentally, and emotionally. More than just a dedicated team, the SWO drives wellness strategies that prioritise inclusion and compassion in caring for our people.

To align staff wellness efforts across our large and diverse healthcare family, the SingHealth Staff Wellness Council brings together representatives from each institution and key domains. This Council facilitates open sharing of insights and best practices across the cluster, enabling institutions to adapt ideas that resonate with their staff.

By weaving wellness into every aspect of our organisational culture, we are building a workforce that is resilient, engaged, and fulfilled. In recognition of our commitment to workplace wellness, we are honoured to receive the Silver Ribbon Mental Health Award and be named among WorkWell Leaders' Top 25 Impact Employers.

Together, we are creating a vibrant workplace where every member of our SingHealth family thrives and flourishes!

MORE STORIES

Large-scale T-cell trial to combat the big C

Where science meets care: Our Academic Medicine story

The doctor who prescribes movement, not just medicine

View all stories

Large-scale T-cell trial to combat the big C

The little red dot is playing a major role in combating the big C (for cancer), a growing burden globally. Led by Professor Toh Han Chong, Senior Consultant, Division of Medical Oncology and Deputy Chief Executive Officer (Strategic Partnerships), National Cancer Centre Singapore, a team of researchers from Singapore have been coordinating the largest global T-cell clinical trial for solid tumours. T-cell therapy is a type of immunotherapy that harnesses the body’s immune cells to fight cancer.

The phase three clinical trial named VANCE, recruited 330 patients with advanced nasopharyngeal cancer or nose cancer across 23 sites in Singapore, Malaysia, Thailand, Taiwan and the United States. A high level of expertise, coordination and precision was required as this type of complex cell therapy is still in its infancy.

Trial participants were separated into two groups: One that underwent both chemotherapy and a type of T-cell therapy called EBV-CTL, while the other received only chemotherapy. While there was no significant difference between the overall survival rates of both groups, researchers discovered after analysing a subset of the group that received both EBV-CTL and chemotherapies, that more positive treatment outcomes may be achieved by identifying biomarkers to improve how the cell therapy is developed and administered. The trial results were published in the high impact factor journal, Annals on Oncology, in September 2024.